Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose: Fluorouracil (5-FU) and leucovorin combination therapy have shown synergistic or additive effect against advanced colorectal cancer, but the frequency of mucositis and diarrhea is increased. Most previous studies have used high dose leucovorin (300∼500 mg/m2). However, some studies of oxaliplatin and 5-FU with low-dose or high-dose leucovorin in Korea have shown similar response rates. Therefore, we studied the necessity of leucovorin and evaluated the objective tumor response rates and toxicities of a regimen of oxaliplatin and 5-FU without leucovorin every 2 weeks in metastatic colorectal cancer patients. Materials and Methods: Twenty-four patients with metastatic colorectal cancer were enrolled between January 2002 and March 2003. Patients received 85 mg/ m2 of oxaliplatin on day 1, a bolus 5-FU 400 mg/m2 on day 1 and a continuous 5-FU infusion at 600 mg/m2/ 22 hours days 1 and 2, every 2 weeks. Results: Of the 24 patients treated, 17 patients received previous 5FU with leucovorin and/or other chemotherapy. Three patients could not be evaluated. Five partial responses were observed with overall response rate of 21% (n=24). Of the previous chemotherapy group (n= 17), 4 partial responses were observed with response rate of 24%. Median overall survival was 18 months (range 4∼ 32 months) and median progression free survival was 4 months (range 2∼6 months). This regimen was well tolerated and only 1 grade 3 anemia was observed. Conclusion: Oxaliplatin/5-FU combination therapy without leucovorin achieved a relatively high response rate even in patients resistant to the previous 5-FU chemotherapy, and toxicity was minimal.
참고문헌 (22)
- "2002 Annual report of Korea Central Cancer Registry published in 2003"
- "Where dowe stand with 5-fluorouracil?", 26, pp.589~605 (1999)
- "The modulation of fluorouracil withleucovorin in metastatic colorectal carcinoma", pp.1419~26 (1989)
- "Prospective randomized comparison offluorouracil versus fluorouracil and high-dose continuous infusionleucovorin calcium for the treatment of advanced measurablecolorectal cancer in patients previously unexposed tochemotherapy", 8, pp.491~501 (1990)
- "Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrumof activity in drug-resistant cell lines of the NationalCancer Institute's Anticancer Drug Screen panel.", 52, pp.1855~65 (1996)
- "Two consecutive phase II studies ofoxaliplatin (L-OHP) for treatment of patients with advancedcolorectal carcinoma who were resistant to previous treatmentwith fluoropyrimidines", 7, pp.95~8 (1996)
- "A phase II trial of oxaliplatin asfirst-line chemotherapy in metastatic colorectal cancer patients", 8, pp.2739~44 (1998)
- "Oxaliplatin with biweekly, low dose leucovorin and bolusand continuous infusion 5-fluorouracil (modified FOLFOX 4)as first-line therapy for patients with metastatic colorectalcancer.", 36, pp.115~20 (2004)
- "Reportingresults of cancer treatment", 47, pp.207~14 (1981)
- "Biochemical modulation of flurouracil:Evidence of significant improvement of survival and quality oflife in patients with advanced colorectal carcinoma", 7, pp.1407~18 (1989)
- "Randomized trial comparing monthly lowdoseleucovorin and flurouracil bolus with bimonthly high doseleucovorin and flurouracil bolus plus continuous infusion foradvanced colorectal cancer:A Frech intergroup study", 15, pp.808~15 (1997)
- "Leucovorin and fluorouracil with or withoutoxaliplatin as first-line treatment in advanced colorectal cancer", 18, pp.2938~47 (2000)
- "Randomised multicentre trial ofchronotherapy with oxaliplatin, fluorouracil, and folinic acid inmetastatic colorectal cancer. International Organization forCancer Chronotherapy", 350, pp.681~6 (1997)
- "Oxaliplatin with high-dose leucovorin and5-fluorouracil 48-hour continuous infusion in pretreated metastaticcolorectal cancer", 33, pp.214~9 (1997)
- "Oxaliplatin, folinic acid and 5-fluorouracil(folfox) in pretreated patients with metastatic advanced cancer", 18, pp.769~75 (1997)
- "Oxaliplatin added to the simplified bimonthlyleucovorin and 5-fluorouracil regimen as second-line therapyfor metastatic colorectal cancer (FOLFOX6).", 35, pp.1338~42 (1999)
- "Bimonthly high-dose leucovorin, 5-fluorouracil infusion andoxaliplatin (FOLFOX3) for metastatic colorectal cancer resistantto the same leucovorin and 5-fluorouracil regimen", 9, pp.1251~3 (1998)
- "Multicenter phase II study of bimonthlyhigh-dose leucovorin,fluorouracil infusion,and oxaliplatin formetastatic colorectal cancer resistant to the same leucovorinand flurouracil regimen", 17, pp.3560~8 (1999)
- "A phase II study of oxaliplatin combined with 5-Fluorouraciland leucovorin (Mayo clinic regimen) in 5-FluororuacilRefractory Colorectal Cancer", 34, pp.218~22 (2002)
- "Combination chemotherapy of oxaliplatin,5-flurouracil,andleucovorin in 5-fluorouracil-pretreated patients with metastaticcolorectal cancer", 33, pp.414~9 (2003)
- "A phase II study of oxaliplatin,5-fluorouracil,and leucovorinin 5-Fluorouracil pretereated metastatic colorectal cancer", 33, pp.99~105 (2001)
- "Combination of oxaliplatin,fluorouracil,and leucovorin inthe treatment of fluoropyrimidine-pretreated patients withmetastatic colorectal cancer", 16, pp.69~74 (2001)